These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 16614197)

  • 1. Marketing drugs too early in testing.
    Begg CB; Brawley O; Califf RM; Demets DL; Ellenberg SS; Kaplan RS
    Science; 2006 Apr; 312(5771):195. PubMed ID: 16614197
    [No Abstract]   [Full Text] [Related]  

  • 2. GATT implementation and generic drug approval.
    Safir PO; Lassman SM
    Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
    [No Abstract]   [Full Text] [Related]  

  • 3. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 4. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 5. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 6. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 8. The regulation of drugs and biologics: fifty years into the future.
    Kuhlik BN
    Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent developments help the defense of drug companies in 10b-5 cases.
    Salpeter AN; Hutchins H
    Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711
    [No Abstract]   [Full Text] [Related]  

  • 10. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 11. The FDA and "privatization"--the drug approval process.
    Rutherford EM
    Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
    [No Abstract]   [Full Text] [Related]  

  • 12. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 13. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

  • 14. US court rules to allow experimental drugs for dying patients.
    Waltz E
    Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988
    [No Abstract]   [Full Text] [Related]  

  • 15. Teaching clinicians about drugs--50 years later, whose job is it?
    Avorn J
    N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
    [No Abstract]   [Full Text] [Related]  

  • 16. [Is it possible to reduce the number of patients studied in drug tests before the drug tested is authorized for marketing?].
    Flamant R; Spriet A; Caulin C; Doyon F; Cazor JL; Jaillon P
    Therapie; 1993; 48(4):329-31. PubMed ID: 8128418
    [No Abstract]   [Full Text] [Related]  

  • 17. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
    Joffe S; Lynch HF
    N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
    [No Abstract]   [Full Text] [Related]  

  • 18. Accelerated approval of oncology drugs: can we do better?
    Ellenberg SS
    J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
    [No Abstract]   [Full Text] [Related]  

  • 19. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
    Lovell MC
    Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
    [No Abstract]   [Full Text] [Related]  

  • 20. Appropriate specifications at the IND stage.
    Geigert J
    Dev Biol Stand; 1997; 91():39-43. PubMed ID: 9413681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.